Mode
Text Size
Log in / Sign up

Deferral of PCI non-inferior to routine PCI before TAVI in coronary artery disease patientsStudy finds delaying heart artery procedure before valve replacement is as safe as doing it first

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider deferring PCI before TAVI in selected coronary artery disease patients based on non-inferiority evidence.

This randomised controlled trial involved 466 patients with coronary artery disease undergoing transcatheter aortic valve implantation (TAVI) across 12 hospitals in the Netherlands. Participants were assigned to either deferral of percutaneous coronary intervention (PCI) or routine PCI before TAVI, with follow-up of 12.0 months. The primary outcome was a composite of all-cause mortality, myocardial infarction, stroke, and major bleeding at 1 year.

Main results showed deferral of PCI was non-inferior to PCI before TAVI for the primary endpoint, with a rate difference of -1.7% (95% CI -9.5 to 6.2) and hazard ratio of 0.89 (95% CI 0.62-1.28). Specifically, 56 (24%) of 233 patients in the deferral group experienced the composite outcome compared to 60 (26%) of 233 in the PCI group. Non-inferiority was established with p=0.0008, but superiority was not shown (p=0.68).

Safety and tolerability data were not reported in the input. Limitations were not specified, but the study design supports causal inference within its context. Funding was from ZonMw.

Practice relevance suggests an initial conservative strategy with PCI deferral can be appropriate in selected patients, though patient-tailored treatment decisions remain essential. Clinicians should interpret these findings in light of individual patient factors and await further evidence on long-term outcomes and safety.

This study looked at patients with coronary artery disease who were getting a procedure called transcatheter aortic valve implantation (TAVI) to replace a heart valve. It involved 466 patients at 12 hospitals in the Netherlands. Researchers compared two approaches: delaying a procedure to open blocked heart arteries (called PCI) until after TAVI, versus doing PCI before TAVI as usual.

The main finding was that delaying PCI was as safe as doing it first over one year. Both groups had similar rates of death, heart attack, stroke, and major bleeding. Specifically, 24% of patients in the delay group and 26% in the PCI-first group had these events, showing no significant difference.

Safety concerns like adverse events were not reported in the study. The main reason to be careful is that this was a single trial with a moderate sample size, so it doesn't prove delaying is better or safe for everyone. Readers should realistically take that delaying PCI might be an appropriate choice for some patients, but treatment decisions should be tailored to individual needs with a doctor's guidance.

What this means for you:
Delaying artery procedure before valve replacement may be as safe, but talk to your doctor for personalized care.

Study Details

Study typeRct
Sample sizen = 466
EvidenceLevel 2
Follow-up12.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Coronary artery disease is common in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to assess whether deferral of percutaneous coronary intervention (PCI) is non-inferior to routine PCI before TAVI in patients with coronary artery disease. METHODS: In this investigator-initiated, open-label, randomised controlled trial, done at 12 hospitals in the Netherlands, TAVI patients with coronary artery disease were randomly assigned in a 1:1 ratio to deferral of PCI or PCI before TAVI. Randomisation was done by use of a web-based system with random block sizes of 2 and 4, and stratification by presence of coronary artery disease involving proximal left anterior descending artery. The primary endpoint was a composite of all-cause mortality, myocardial infarction, stroke, and major bleeding at 1 year. Non-inferiority testing was done in the intention-to-treat population against the prespecified margin of 11 percentage points. The study is registered with ClinicalTrials.gov (NCT05078619) and long-term follow-up is ongoing. FINDINGS: Between Oct 7, 2021, and Nov 19, 2024, 466 patients were enrolled: 233 were assigned to deferral of PCI and 233 to PCI before TAVI. Median age was 81 years (IQR 78-84), and 166 (36%) of 466 patients were female. The primary endpoint occurred in 56 (24%) of 233 patients in the deferral group as compared with 60 (26%) of 233 patients in the PCI group (rate difference -1·7% [95% CI -9·5 to 6·2]; hazard ratio 0·89 [95% CI 0·62-1·28]; p=0·0008 for non-inferiority; p=0·68 for superiority). INTERPRETATION: In patients with coronary artery disease undergoing TAVI, deferral of PCI was non-inferior to PCI before TAVI for the 1-year composite of all-cause mortality, myocardial infarction, stroke, and major bleeding. These findings suggest that an initial conservative strategy can be appropriate in selected patients, although patient-tailored treatment decisions remain essential. FUNDING: ZonMw.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.